Celadon Pharmaceuticals (CEL) Stock Chart & Stock Price History GBX 13.80 -1.70 (-10.97%) (As of 08:35 AM ET) Add Compare Share Share Chart Stock AnalysisChartCompetitorsHeadlines Celadon Pharmaceuticals Stock Price Performance 5 Day Performance-50.71%1 Month Performance-45.45%3 Month Performance-44.56%6 Month Performance-85.77%Year-To-Date Performance-88.00%1 Year Performance-87.45% Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide CEL Stock Chart for Thursday, November, 21, 2024 CEL Chart by TradingView Celadon Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/20/2024GBX 18.40GBX 15.50-15.76%GBX 19GBX 15.2067,711 shs£10.67 million11/19/2024GBX 19.80GBX 18.40-7.07%GBX 19GBX 16169,034 shs£12.67 million11/18/2024GBX 28GBX 19.80-29.29%GBX 21GBX 14324,669 shs£13.63 million11/15/2024GBX 26GBX 28+7.69%GBX 30GBX 267,585 shs£19.28 million11/14/2024GBX 26.40GBX 26-1.52%GBX 28GBX 267,717 shs£17.90 million11/13/2024GBX 26GBX 26.40+1.54%GBX 27GBX 2612,804 shs£18.18 million Get the Latest News and Ratings for CEL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/12/2024GBX 27GBX 26-3.70%GBX 27GBX 2610,188 shs£17.90 million11/11/2024GBX 26.50GBX 27+1.89%GBX 27GBX 26160,202 shs£18.59 million11/08/2024GBX 26GBX 27+3.85%GBX 2,650GBX 25439,005 shs£18.59 million11/07/2024GBX 28GBX 26-7.14%GBX 30GBX 26166,056 shs£17.90 million11/06/2024GBX 25.20GBX 28+11.11%GBX 30GBX 2673,442 shs£19.28 million11/05/2024GBX 26.60GBX 25.20-5.26%GBX 28GBX 2519,781 shs£17.35 million11/04/2024GBX 27.50GBX 26.60-3.27%GBX 26.60GBX 26.60376 shs£18.31 million11/01/2024GBX 30GBX 28.70-4.33%GBX 30GBX 25.3826,527 shs£19.76 million10/31/2024GBX 25GBX 30+20.00%GBX 30GBX 27.5030 shs£20.66 million10/30/2024GBX 28.50GBX 25-12.28%GBX 30GBX 2524,829 shs£17.21 million10/29/2024GBX 28.17GBX 28.50+1.19%GBX 31GBX 2790,253 shs£19.62 million10/28/2024GBX 29.50GBX 28.17-4.53%GBX 30.99GBX 28136,837 shs£19.39 million10/25/2024GBX 27.50GBX 28.17+2.42%GBX 31GBX 279,423 shs£19.39 million10/24/2024GBX 30.40GBX 27.50-9.54%GBX 31GBX 26.55390,229 shs£18.93 million10/23/2024GBX 26.27GBX 30.40+15.72%GBX 31GBX 25440,125 shs£20.93 million10/22/2024GBX 25.30GBX 26.27+3.83%GBX 27GBX 25.3845,292 shs£18.09 million10/21/2024GBX 27.50GBX 25.30-8.00%GBX 27.74GBX 25.2588,117 shs£17.42 million Related Companies Cambridge Nutritional Sciences Stock Chart Beacon Energy Stock Chart Curzon Energy Stock Chart Vodafone Group Public Stock Chart BT Group Stock Chart BBGI Global Infrastructure Stock Chart Pacific Horizon Investment Trust Stock Chart Shield Therapeutics Stock Chart Chill Brands Group Stock Chart Provexis Stock Chart Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (LON:CEL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
